TCRT revenueQ2 2026$0
- FY YoY
- -50.0%
TCRT revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $5.0K, down 50.0% from fiscal 2024. It rose in 2 of the last 4 fiscal years.
Alaunos Therapeutics Inc. (TCRT) financials
For the twelve months ended Jun 30, 2026, Alaunos Therapeutics Inc. reported $3.0K of revenue and -$4.01M of net income.
- Revenue, TTM
- $3.0K
- Revenue growth, YoY
- -50.0%
- Net income, TTM
- -$4.01M
- Net margin
- -133666.7%
- Cash
- $124.0K
- P/S
- 2298.18
- Market cap
- $6.9M
FY2016FY2025
FY2016FY2025
FY2016FY2025
TCRT revenue and earnings growth
TCRT net incomeQ2 2026-$952.0K
TCRT net income was -$952.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.05M a year earlier. For the full fiscal 2025 it was -$4.18M, compared with -$4.68M in fiscal 2024.
TCRT EPSQ2 2026-$0.41
TCRT diluted EPS was -$0.41 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.20, compared with -$2.92 in fiscal 2024.
TCRT free cash flowQ4 2025-$553.0K
TCRT free cash flow was -$553.0K in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$592.0K a year earlier. For the full fiscal 2025 it was -$2.97M, compared with -$4.97M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $10.0K | $5.0K | $2.92M | $398.0K | $0 | - | $146.0K | $15.90M | $6.86M |
| Research and development | $1.36M | $362.0K | $16.28M | $25.02M | $49.64M | $52.70M | $38.33M | $34.13M | $45.08M | $157.79M |
| Selling, general and admin | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M | $27.66M | $19.53M | $19.92M | $14.80M | $14.38M |
| Operating income | -$4.22M | -$4.81M | -$34.27M | -$35.10M | -$77.55M | -$80.36M | -$57.86M | -$53.91M | -$53.49M | -$165.31M |
| Interest expense | - | $0 | $1.92M | $3.15M | $1.19M | - | - | - | - | - |
| Income tax | $0 | - | - | - | - | - | - | - | - | - |
| Net income | -$4.18M | -$4.68M | -$4.68M | -$37.73M | -$78.75M | -$79.98M | -$117.80M | -$53.12M | -$54.32M | -$165.30M |
| EPS, basic | -$2.20 | -$2.92 | -$21.97 | -$391.50 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 |
| EPS, diluted | -$2.20 | -$2.92 | -$21.97 | -$391.50 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 |
| Diluted shares | 1.9M | 1.6M | 1.6M | 96,502.36 | 1.4M | 1.4M | 1.1M | 958,067.733 | 912,921.76 | 869,276.42 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.39M | $1.09M | $6.06M | $53.00M | $76.05M | $115.07M | $79.74M | $61.73M | $71.33M | $81.44M |
| Receivables | $3.0K | $5.0K | $1.0K | $4.0K | $1.11M | $4.67M | $3.33M | $1.86M | $19.0K | $21.0K |
| Current assets | $1.99M | $2.75M | $8.26M | $53.80M | $78.83M | $130.59M | $105.49M | $84.28M | $90.78M | $104.88M |
| Total assets | $2.97M | $2.75M | $8.26M | $64.94M | $94.86M | $146.34M | $109.11M | $95.05M | $105.61M | $106.35M |
| Current liabilities | $813.0K | $692.0K | $1.96M | $24.17M | $16.04M | $18.37M | $12.53M | $9.48M | $20.86M | $15.81M |
| Short-term debt | - | - | $0 | $16.77M | $7.87M | $0 | - | - | - | - |
| Long-term debt | - | $0 | $0 | $0 | $16.25M | $0 | - | - | - | - |
| Total debt | - | $0 | $0 | $16.77M | $24.12M | $0 | - | - | - | - |
| Total liabilities | $813.0K | $692.0K | $1.96M | $26.38M | $36.81M | $22.36M | $14.10M | $9.49M | $58.42M | $58.33M |
| Shareholders' equity | $2.15M | $2.06M | $6.31M | $38.55M | $58.06M | $123.98M | $95.01M | $85.56M | -$96.81M | -$77.30M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.87M | -$4.97M | -$30.14M | -$29.23M | -$61.47M | -$57.01M | -$40.85M | -$49.46M | -$54.67M | -$58.33M |
| Capital expenditures | $98.0K | $0 | $197.0K | $216.0K | $3.32M | $9.78M | $284.0K | $459.0K | $737.0K | $551.0K |
| Free cash flow | -$2.97M | -$4.97M | -$30.34M | -$29.45M | -$64.79M | -$66.79M | -$41.14M | -$49.92M | -$55.41M | -$58.88M |
| Investing cash flow | -$98.0K | $0 | $1.35M | -$193.0K | -$3.32M | -$9.78M | -$284.0K | -$459.0K | -$737.0K | -$551.0K |
| Financing cash flow | $3.26M | $0 | -$18.14M | $6.37M | $25.78M | $102.12M | $59.15M | $40.31M | $45.30M | -$788.0K |
| Share repurchases | - | - | $0 | $45.0K | $0 | - | $653.0K | $1.62M | $0 | $2.0K |
| Stock-based compensation | $796.0K | $435.0K | $2.80M | $3.53M | $10.77M | $6.83M | $6.34M | $7.53M | $8.45M | $8.45M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | $290.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -50.0% | 100.0% | -99.8% | 634.2% | - | - | - | -99.1% | 131.7% | - |
| Operating margin | -84500.0% | -48120.0% | -685340.0% | -1201.4% | -19484.7% | - | - | -36921.9% | -336.4% | -2409.4% |
| Net margin | -83520.0% | -46790.0% | -93580.0% | -1291.2% | -19786.7% | - | - | -36381.5% | -341.7% | -2409.2% |
| Free cash flow margin | -59340.0% | -49710.0% | -606780.0% | -1007.8% | -16279.1% | - | - | -34189.0% | -348.5% | -858.1% |
| Return on equity | -194.0% | -226.8% | -74.2% | -97.9% | -135.6% | -64.5% | -124.0% | -62.1% | - | - |
| Return on assets | -140.8% | -169.8% | -56.6% | -58.1% | -83.0% | -54.6% | -108.0% | -55.9% | -51.4% | -155.4% |
| Current ratio | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
| Debt to equity | - | 0.00 | 0.00 | 0.43 | 0.42 | 0.00 | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3.0K | $0 | $0 | $2.0K | $4.0K | $0 | $4.0K | $1.0K | $1.0K | $0 |
| Research and development | $388.0K | $427.0K | $361.0K | $469.0K | $185.0K | $347.0K | -$86.0K | $143.0K | $180.0K | $126.0K | $933.0K | $3.66M |
| Selling, general and admin | $564.0K | $585.0K | $549.0K | $718.0K | $854.0K | $747.0K | $845.0K | $1.01M | $990.0K | $1.62M | $2.43M | $3.58M |
| Operating income | -$952.0K | -$1.01M | -$907.0K | -$1.19M | -$1.04M | -$1.09M | -$755.0K | -$1.15M | -$1.17M | -$1.74M | -$7.95M | -$8.66M |
| Interest expense | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$952.0K | -$1.01M | -$893.0K | -$1.16M | -$1.05M | -$1.07M | -$742.0K | -$1.13M | -$1.13M | -$1.68M | $22.62M | -$8.48M |
| EPS, basic | -$0.41 | -$0.59 | - | -$0.55 | -$0.63 | -$0.67 | -$0.46 | -$0.70 | -$0.71 | -$1.05 | - | -$5.30 |
| EPS, diluted | -$0.41 | -$0.59 | - | -$0.55 | -$0.63 | -$0.67 | -$0.46 | -$0.70 | -$0.71 | -$1.05 | - | -$5.30 |
| Diluted shares | 2.4M | 1.9M | - | 2.2M | 1.7M | 1.6M | - | 1.6M | 1.6M | 1.6M | - | 1.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $124.0K | $354.0K | $1.39M | $1.94M | $2.88M | $319.0K | $1.09M | $1.68M | $2.46M | $4.14M | $6.06M | $11.94M |
| Receivables | $0 | $0 | $3.0K | $0 | $2.0K | $2.0K | $5.0K | $0 | $4.0K | $1.0K | $1.0K | $0 |
| Current assets | $666.0K | $970.0K | $1.99M | $2.69M | $3.74M | $1.07M | $2.75M | $3.55M | $4.68M | $6.04M | $8.26M | $12.87M |
| Total assets | $1.52M | $1.88M | $2.97M | $3.72M | $4.74M | $2.12M | $2.75M | $3.55M | $4.68M | $6.04M | $8.26M | $19.44M |
| Current liabilities | $864.0K | $595.0K | $813.0K | $921.0K | $1.07M | $1.06M | $692.0K | $826.0K | $907.0K | $1.24M | $1.96M | $4.68M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Long-term debt | - | - | - | - | - | - | $0 | - | - | $0 | $0 | - |
| Total debt | - | - | - | - | - | - | $0 | - | - | $0 | $0 | - |
| Total liabilities | $864.0K | $595.0K | $813.0K | $921.0K | $1.07M | $1.06M | $692.0K | $826.0K | $907.0K | $1.24M | $1.96M | $5.54M |
| Shareholders' equity | $652.0K | $1.29M | $2.15M | $2.80M | $3.66M | $1.06M | $2.06M | $2.72M | $3.77M | $4.80M | $6.31M | $13.90M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$300.0K | -$1.03M | -$552.0K | -$844.0K | -$701.0K | -$772.0K | -$592.0K | -$781.0K | -$1.68M | -$1.92M | -$7.38M | -$6.37M |
| Capital expenditures | - | - | $1.0K | - | - | - | $0 | $0 | $0 | $0 | $0 | $1.0K |
| Free cash flow | - | - | -$553.0K | - | - | - | -$592.0K | -$781.0K | -$1.68M | -$1.92M | -$7.38M | -$6.38M |
| Investing cash flow | - | - | -$1.0K | - | - | - | $0 | $0 | $0 | $0 | $1.50M | $1.0K |
| Financing cash flow | - | - | $0 | $0 | - | - | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Stock-based compensation | $246.0K | $141.0K | $243.0K | $301.0K | $184.0K | $68.0K | $81.0K | $80.0K | $101.0K | $172.0K | $250.0K | $726.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | -25.0% | - | -100.0% | 100.0% | 300.0% | - | 0.0% | - | -90.9% | -100.0% |
| Operating margin | - | - | -30233.3% | - | - | -54600.0% | -18875.0% | - | -29150.0% | -174200.0% | -794900.0% | - |
| Net margin | - | - | -29766.7% | - | - | -53650.0% | -18550.0% | - | -28225.0% | -168200.0% | 2261800.0% | - |
| Free cash flow margin | - | - | -18433.3% | - | - | - | -14800.0% | - | -42025.0% | -191700.0% | -738500.0% | - |
| Current ratio | 0.77 | 1.63 | 2.45 | 2.92 | 3.48 | 1.00 | 3.98 | 4.30 | 5.16 | 4.87 | 4.22 | 2.75 |
| Debt to equity | - | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 | - |
Source: XBRL data Alaunos Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-150, first reported Aug 14, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TCRT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TCRT | $3.0K | -50.0% | -$4.01M | -133666.7% | $6.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
TCRT FAQ
6 questionsWhat is TCRT revenue?
Alaunos Therapeutics Inc. (TCRT) reported $3.0K of revenue for the twelve months ended Jun 30, 2026. That is down 50.0% from the year before. Revenue for fiscal 2025 was $5.0K.Is TCRT profitable?
No. Alaunos Therapeutics Inc. reported a net loss of $4.01M for the twelve months ended Jun 30, 2026.How much cash and debt does TCRT have?
Alaunos Therapeutics Inc. reported $124.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is TCRT revenue growing?
Alaunos Therapeutics Inc.'s revenue changed -50.0% in fiscal 2025, to $5.0K.When did TCRT last report financial results?
The latest statements here come from Alaunos Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this TCRT financial data come from?
Quantisnow builds these statements from the structured XBRL data Alaunos Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.